/wp-content/uploads/logo.png00David Anderson/wp-content/uploads/logo.pngDavid Anderson2022-05-31 04:40:512022-05-31 08:06:34Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)
/wp-content/uploads/logo.png00eallison/wp-content/uploads/logo.pngeallison2022-05-25 09:43:382022-05-25 09:58:16Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)
/wp-content/uploads/logo.png00David Anderson/wp-content/uploads/logo.pngDavid Anderson2022-02-07 05:05:122022-02-10 08:50:07Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
/wp-content/uploads/logo.png00Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-19 14:48:512022-02-03 18:59:03Endeavor Biomedicines doses first patient in phase 2 clinical trial of Taladegib (ENV-101) for idiopathic pulmonary fibrosis; appoints chief medical officer
/wp-content/uploads/logo.png00Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-19 15:00:242022-02-03 19:02:50Endeavor Biomedicines Licenses Ulk1/2 Inhibitor Program From Salk Institute And Sanford Burnham Prebys To Broaden Its Precision Oncology Pipeline
/wp-content/uploads/logo.png00Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-19 15:01:212022-02-03 19:01:25Endeavor Biomedicines Launches With $62 Million Series A Financing And Mission To Reverse The Course Of Devastating Pulmonary Disease
